Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir post-exposure prophylaxis study in Bundibugyo virus disease
PACTR202609875219832Phase 2Not yet recruiting
- Sponsor
- Institut National de la Recherche Biomedicale
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of molnupiravir in Bundibugyo ebolavirus infection (BDBV) and Ebola virus disease (EVD) (2 arms), sponsored by Institut National de la Recherche Biomedicale. Primary endpoints: Adverse events and serious adverse events, Laboratory safety values and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
molnupiravir
03
Conditions
Bundibugyo ebolavirus infection (BDBV)Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202609875219832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609875219832.